Analysis Of The Biotech Clinical Trials Ecosystem: Market Growth Drivers, CRO Performance Metrics, And The Shift Toward Unified Digital Platforms

The biotech clinical trials ecosystem is expanding rapidly post-COVID, projected to reach $150 billion by 2030 with a 6-7% CAGR. Growth is fueled by oncology, gene therapy, and the rise of Global Capability Centers in the APAC region. While major CROs like IQVIA dominate, specialized firms like Medpace succeed through internal labs. The industry is shifting toward unified digital platforms, with Medidata and Veeva leading over fragmented solutions, focusing on critical metrics like rapid site activation, enrollment velocity, and database locking to ensure superior clinical trial data quality